StatNews: These pricey cholesterol drugs aren’t selling, and that has the biotech industry sweating

StatNews: These pricey cholesterol drugs aren’t selling, and that has the biotech industry sweating

A year ago, two new drugs that used a novel mechanism to drive down cholesterol levels came on the market, and were promptly crowned as blockbusters in-waiting. Analysts estimated sales at more than $3 billion a year.